A major milestone in aging research has been achieved with the release of the first comprehensive atlas of cellular senescence in human tissues. Developed through the National Institutes of Health (NIH) Cellular Senescence Network (SenNet), the initiative provides the most detailed map to date of senescent cells, often referred to as “zombie cells” and their role in the aging process.

The newly published findings represent the first coordinated effort to analyze senescent cells at both single-cell and spatial resolution across human tissues. Researchers used advanced omics technologies to identify where these cells accumulate, how they differ across tissue and cell types, and how their biological characteristics vary even within the same type of cell. The results suggest that cellular senescence is not a single, uniform state but rather a diverse collection of distinct cellular subtypes.

Senescent cells are damaged or aged cells that permanently stop dividing but remain active in the body. Over time, they accumulate in tissues and release inflammatory molecules and other harmful substances that contribute to tissue damage. Their presence has been linked to age-related conditions, including arthritis, cancer, and Alzheimer’s disease.

The atlas is expected to serve as a valuable resource for scientists investigating the biological mechanisms of aging and developing interventions to target senescent cells. By providing a detailed understanding of where senescent cells are found and how they behave, the project lays the groundwork for more precise therapeutic strategies aimed at reducing their harmful effects.

While research efforts have largely focused on mapping and characterizing senescent cells, interest continues to grow in senolytic therapies, drugs designed to selectively eliminate these cells. Preclinical studies in aged mice have shown that clearing a portion of senescent cells can improve tissue function and reverse several age-related disorders. However, despite encouraging animal data, relatively few large-scale clinical trials have evaluated early senolytic treatments, such as the combination of dasatinib and quercetin, in humans.

The SenNet atlas marks an important step toward advancing both the scientific understanding of aging and the future development of therapies that may help delay or reduce age-related diseases.